We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Trials Test New Biologic, Old Therapeutic Concept

Beverly Merz
JAMA. 1986;256(10):1249. doi:10.1001/jama.1986.03380100023004.
Text Size: A A A
Published online


TUMOR NECROSIS FACTOR (TNF) is the most recent biologic response modifier to reach clinical trials in cancer therapy. Yet it is the direct descendant of one of the earliest attempts to provoke an antitumor immune response.

The rationale for therapy with TNF—a protein secreted by macrophages challenged by bacterial endotoxins—dates to the late 1800s, when physicians noticed that cancer patients who had spontaneous tumor regression often also had bacterial infections. In 1893, a New York city physician, William Coley, MD, began to treat cancer patients with a cocktail of bacterial products, which came to be known as Coley's toxins. The patients usually developed high fevers, and, in some, tumors regressed.

In 1934, the American Medical Association labeled Coley's toxins as the only known systemic treatment for cancer. But Coley's toxins proved to be less reliable in achieving remissions than did radiation and chemotherapy, and in the 1960s the treatment was


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.